

Cover Story
Free
By Matthew Bin Han Ong
FDA has created a framework for evaluating the use of real-world evidence to support additional indications for already approved drugs as well as to satisfy drug post-marketing study requirements.
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for January
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74

















